Department of Radiation Oncology, Ajou University School of Medicine, 164 Worldcup-ro, Yeongtong-gu, Suwon, 16499, Republic of Korea.
Med Oncol. 2021 Nov 5;39(1):5. doi: 10.1007/s12032-021-01604-9.
The purpose of this study was to investigate the impact of the coronavirus disease 2019 (COVID-19) pandemic on patients undergoing radiotherapy by comparing the patterns of unplanned radiotherapy interruption before and after the COVID-19 pandemic. We enrolled patients who received their first dose of radiotherapy for breast cancer between January 28 and July 31, 2019 and between January 28, 2020, and July 31, 2020. We compared the radiotherapy interruption patterns in 2019 with those in 2020 to analyze the impact of the COVID-19 pandemic on treatment interruption. Between January 28 and July 31, 2019, 287 patients with breast cancer received radiotherapy. Among them, 19 patients (6.6%) experienced treatment interruption; the reasons for treatment interruption were radiotherapy-related side effects (10 patients, 52.6%), other medical reasons (three patients, 15.8%), and personal reasons (six patients, 31.6%). Between January 28 and July 31, 2020, 279 patients with breast cancer received radiotherapy. Among them, 23 patients (8.2%) experienced treatment interruption; the reasons for treatment interruption were radiotherapy-related side effects (eight patients, 35%) and COVID-19 screening clinic-related reasons (six patients, 26.1%). Among the six patients with screening clinic-related causes of radiotherapy interruption, five had asymptomatic fever and one had mild cold-like symptoms. The duration of treatment interruption was longer in patients with screening clinic-related interruptions than in those with interruptions because of other causes (p = 0.019). Multivariate analysis showed that cancer stage and radiotherapy volume did not significantly affect treatment interruption. The radiotherapy of certain patients was suspended despite the lack of a confirmed COVID-19 diagnosis. Precise and systematic criteria for the management of patients with suspected COVID-19 are needed, and the opinion of radiation oncologist in charge of the patient must also be considered.
本研究旨在通过比较 COVID-19 大流行前后计划外放疗中断的模式,来探讨 COVID-19 大流行对接受放疗的患者的影响。我们纳入了 2019 年 1 月 28 日至 7 月 31 日和 2020 年 1 月 28 日至 7 月 31 日期间首次接受乳腺癌放疗的患者。我们比较了 2019 年和 2020 年的放疗中断模式,以分析 COVID-19 大流行对治疗中断的影响。2019 年 1 月 28 日至 7 月 31 日期间,287 例乳腺癌患者接受了放疗。其中,19 例(6.6%)患者发生治疗中断;治疗中断的原因包括放疗相关副作用(10 例,52.6%)、其他医疗原因(3 例,15.8%)和个人原因(6 例,31.6%)。2020 年 1 月 28 日至 7 月 31 日期间,279 例乳腺癌患者接受了放疗。其中,23 例(8.2%)患者发生治疗中断;治疗中断的原因包括放疗相关副作用(8 例,35%)和 COVID-19 筛查门诊相关原因(6 例,26.1%)。在因筛查门诊而中断放疗的 6 例患者中,有 5 例无症状发热,1 例轻度类似感冒的症状。因筛查门诊相关原因中断放疗的患者,其治疗中断时间长于因其他原因中断放疗的患者(p=0.019)。多变量分析显示,癌症分期和放疗量并未显著影响治疗中断。尽管没有确诊 COVID-19,某些患者的放疗仍被暂停。需要针对疑似 COVID-19 患者制定准确和系统的管理标准,还必须考虑负责患者的放射肿瘤学家的意见。